Alternating radiotherapy and chemotherapy for inoperable stage III non–small-cell lung cancer: long-term results of two phase II GOTHA trials

Mirimanoff, René-Olivier; Moro, D.; Bolla, M.; Michel, G; Brambilla, Christian; Mermillod, Bernadette; Miralbell, Raymond; Alberto, P.

doi:10.1016/s0360-3016(98)00246-6

Cited by 13 publications

(5 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The MST and 2-year survival rates were similar between arms of RT and RT+CHT (table 2). The alternating HFXRT-CHT (rather similar to the abovementioned schedule) was tested in GOTHA I and II trials [25], giving an MST of 13.6 months and a 2-year survival rate of 27%, with acceptable toxicity. The rates were better than those reported by Blanke et al, although the study included patients with KPS of 70-100.…”

Section: Resultsmentioning

confidence: 99%

Treatment of Inoperable Stage III and IV Non-Small-Cell Lung Cancer: The ‘Average’Radiotherapist’s Point of View

Plataniotis

Theofanopoulou²

2001

Oncol Res Treat

View full text Add to dashboard Cite

Stage III non-small-cell lung cancer (NSCLC) presents a major therapeutic problem for the radiation oncologist who treats patients outside of clinical trials. It is a heterogeneous disease with great variation of the clinical extent, and the optimal therapeutic decision must be based on various parameters: the most important unfavorable characteristics are represented by a low Karnofsky performance status, weight loss > 5%, locally too advanced disease (e.g. T4, positive pleural effusion), intensive symptomatology, and distant metastases. The presence of these factors advocates the use of short hypofractionated radiotherapy (RT) schemes of one or two fractions (e.g., 1 × 10 Gy, 2 × 8.5 Gy), which results in fast and effective palliation. Radical treatment must be given to patients without the above-mentioned unfavorable characteristics. Results from randomized clinical trials support the use of high RT doses, preferably hyperfractionated/ accelerated. The CHART schedule could be used in case of squamous-cell histology. Elderly patients could be treated by the standard scheme of 30 × 2 Gy (or equivalent). Chemotherapy reduces the risk of (other than brain) distant metastases and improves the median survival time, especially for patients with non-squamous-cell NSCLC. Platinum-based chemotherapy is usually administered in conjunction with RT as inductive and/or concurrent. Patients of stage IV are probably candidates for chemotherapy in case of good performance status and for a short-term radiotherapy if local symptoms are predominant.

show abstract

Section: Resultsmentioning

confidence: 99%

Treatment of Inoperable Stage III and IV Non-Small-Cell Lung Cancer: The ‘Average’Radiotherapist’s Point of View

Plataniotis

Theofanopoulou²

2001

Oncol Res Treat

View full text Add to dashboard Cite

show abstract

“…Investigators from two consecutive phase II Groupe d'Oncologie Thoracique Alpine (GOTHA) trials (the first initiated in 1986) recently published their results [12]. Patients were treated with an AHFX RT schedule of 63 Gy in 1.5-Gy twice-daily fractions, administered concurrently with either cisplatin with mitomycin and vindesine or cisplatin with vinblastine.…”

Section: Treatment Of Non-small-cell Lung Cancermentioning

confidence: 99%

Hyperfractionated radiotherapy for lung cancer

Gressen

2000

Curr Oncol Rep

View full text Add to dashboard Cite

In several recent clinical trials, hyperfractionated or accelerated hyperfractionated thoracic radiation therapy has improved survival over conventional radiotherapy among patients with either stage III non-small-cell lung cancer or limited-stage small-cell lung cancer. Combinations of novel chemotherapy agents such as taxanes and gemcitabine with hyperfractionated or accelerated hyperfractionated radiotherapy may further improve survival, although toxicity must be closely followed. Attempts to minimize the amount of normal tissue radiated through either three-dimensional treatment planning or use of a radioprotector (such as amifostine) may allow therapeutic escalation with chemoradiation and further success at treating the number one cause of cancer-related mortality in the United States.

show abstract

“…Patients with pathologically or cytologically documented squamous cell carcinoma, adenocarcinoma, large cell, or undifferentiated NSCLC with either inoperable Stage IIIA or IIIB (with the exception of patients with pleural or pericardial effusion), or medically inoperable Stage I or II were considered to be eligible. This series of 23 consecutive patients represents a subgroup of all inoperable NSCLC seen in our department, who could not be enrolled in on-going trials of combined radiochemotherapy available at this time, namely the GOTHA I and II trials (18,19). These priority protocols in our department consisted of different schemes of combination cisplatin-based chemotherapy, rapidly alternated with hyperfractionated-accelerated RT.…”

Section: Eligibility and Study Parametersmentioning

confidence: 99%

“…The radiotherapy scheme was adapted from GOTHA I and II, the major difference being that it did not include any interruption. (In GOTHA I and II, a 2-week split was mandatory for the administration of the second cycle of chemotherapy) (18,19).…”

Section: Treatment Schemementioning

confidence: 99%

See 1 more Smart Citation

Hyperfractionated accelerated radiotherapy (hart) for inoperable, nonmetastatic non-small cell lung carcinoma of the lung (nsclc): results of a phase ii study for patients ineligible for combination radiochemotherapy

Koutaissoff

Wellmann

Coucke

et al. 1999

International Journal of Radiation Oncology*Biology*Physics

Self Cite

View full text Add to dashboard Cite

Alternating radiotherapy and chemotherapy for inoperable stage III non–small-cell lung cancer: long-term results of two phase II GOTHA trials

Cited by 13 publications

References 44 publications

Treatment of Inoperable Stage III and IV Non-Small-Cell Lung Cancer: The ‘Average’Radiotherapist’s Point of View

Treatment of Inoperable Stage III and IV Non-Small-Cell Lung Cancer: The ‘Average’Radiotherapist’s Point of View

Hyperfractionated radiotherapy for lung cancer

Hyperfractionated accelerated radiotherapy (hart) for inoperable, nonmetastatic non-small cell lung carcinoma of the lung (nsclc): results of a phase ii study for patients ineligible for combination radiochemotherapy

Contact Info

Product

Resources

About